Failed Pipeline Counterfactual Training Diagram

Strengths

• Real failed pipeline data is difficult to replace with synthetic data, offering strong scarcity
• Pharmaceutical companies' willingness to monetize stock data has significantly increased amid the AI pharma boom
• Desensitization and dimension reduction technologies lower privacy compliance resistance, making transactions more viable

Weaknesses

• Inconsistent recording formats for failure data lead to high cleaning and standardization costs
• Pharma legal teams are extremely cautious about data outflows, resulting in long contracting cycles
• The current number of paying-capable AI pharma platforms is limited, and the market still requires education

Opportunities

• Insilico Medicine's $2.5 billion asset transaction drives AI pharma asset valuation systems and expands procurement budgets
• The AI4S industrialization wave, such as ByteDance's spin-off of Anew Labs, expands the potential customer base
• Regulatory rules for the secondary use of clinical data are gradually becoming clearer, providing a definite compliance path

Threats

• MeiraGTx-style buybacks of failed projects encourage pharmaceutical companies to retain pipelines themselves, reducing external data supply
• Advances in synthetic data technology may replace some real counterfactual training samples
• Large pharmaceutical companies building their own AI capabilities reduce procurement of external failure data